ATE477275T1 - Antikörper gegen cd28 - Google Patents

Antikörper gegen cd28

Info

Publication number
ATE477275T1
ATE477275T1 AT01995797T AT01995797T ATE477275T1 AT E477275 T1 ATE477275 T1 AT E477275T1 AT 01995797 T AT01995797 T AT 01995797T AT 01995797 T AT01995797 T AT 01995797T AT E477275 T1 ATE477275 T1 AT E477275T1
Authority
AT
Austria
Prior art keywords
antibodies against
antibody
receptor
interaction
blocks
Prior art date
Application number
AT01995797T
Other languages
English (en)
Inventor
Jean-Paul Soulillou
Genevieve Laflamme
Bernard Vanhove
Daniel Olive
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE477275T1 publication Critical patent/ATE477275T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01995797T 2000-12-26 2001-12-26 Antikörper gegen cd28 ATE477275T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0017025 2000-12-26
PCT/FR2001/004203 WO2002051871A2 (fr) 2000-12-26 2001-12-26 Anticorps anti-cd28

Publications (1)

Publication Number Publication Date
ATE477275T1 true ATE477275T1 (de) 2010-08-15

Family

ID=8858197

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01995797T ATE477275T1 (de) 2000-12-26 2001-12-26 Antikörper gegen cd28

Country Status (9)

Country Link
US (1) US7723482B2 (de)
EP (1) EP1345969B1 (de)
JP (1) JP4066166B2 (de)
AT (1) ATE477275T1 (de)
DE (1) DE60142794D1 (de)
DK (1) DK1345969T3 (de)
ES (1) ES2353273T3 (de)
PT (1) PT1345969E (de)
WO (1) WO2002051871A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
EP2363410B1 (de) * 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation MUC1-Isoformen
DK2363410T3 (en) * 2003-08-26 2018-01-15 Minerva Biotechnologies Corp ISOFORMER OF MUC1
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
EP2700651B1 (de) 2008-07-18 2019-04-10 Bristol-Myers Squibb Company Zur Bindung von CD28 monovalente Zusammensetzungen und Verfahren zur Verwendung
EP3281955A1 (de) 2008-10-02 2018-02-14 Aptevo Research and Development LLC Multitarget-bindungsproteine mit cd86-antagonist
EP2210902A1 (de) 2009-01-14 2010-07-28 TcL Pharma Rekombinante monovalente Antikörper
WO2010085879A1 (en) * 2009-01-28 2010-08-05 Industrial Technology Research Institute Urine and serum biomarkers associated with diabetic nephropathy
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
US8785604B2 (en) * 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies
EP2361935A1 (de) * 2010-02-18 2011-08-31 TcL Pharma Humanisierte Anti-CD28-Antikörper
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP3091032A1 (de) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Cd3-spezifischer, humanisierter antikörper oder fragment davon
MY189590A (en) 2015-11-18 2022-02-18 Merck Sharp & Dohme Ctla4 binders
CA3003777A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1/ctla4 binders
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
EP3551034A1 (de) 2016-12-07 2019-10-16 Progenity, Inc. Verfahren, vorrichtungen und systeme zur detektion des magen-darm-trakts
EP3600416B1 (de) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Behandlung einer erkrankung des gastrointestinaltraktes mit einem immunmodulatorischen mittel, das mit einer einnehmbaren vorrichtung freigesetzt wird.
KR20200131260A (ko) * 2018-03-15 2020-11-23 비온드 바이오로직스 엘티디 가용성 면역 수용체 cd28을 감소시키기 위한 방법 및 조성물
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN112351820B (zh) 2018-06-21 2024-10-11 瑞泽恩制药公司 双特异性抗psma x抗cd28抗体及其用途
CN120535649A (zh) 2018-08-30 2025-08-26 免疫生物公司 单链嵌合多肽和其用途
AU2019328575B2 (en) 2018-08-30 2024-07-11 Immunitybio, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
JP7397874B2 (ja) 2018-08-30 2023-12-13 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
US20210355216A1 (en) 2018-10-05 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and systems for controlling the agonistic properties of antibody variable domains by light
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
CA3130351A1 (en) 2019-03-14 2020-09-17 Motti HAKIM Small shedding blocking agents
EP3962493A2 (de) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Verfahren zur modulation der immunreaktivität/konzentration von irf oder sting oder zur behandlung von krebs mit der verabreichung eines sting-modulators und/oder eines purinergischen rezeptormodulators oder eines postzellularen signalisierungsfaktors
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
AU2020395977A1 (en) 2019-12-02 2022-06-23 Biond Biologics Ltd. Use of MMP inhibition
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
AU2021220196A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of activating regulatory T cells
US12187763B2 (en) 2020-02-11 2025-01-07 Immunitybio, Inc. Chromatography resin and uses thereof
JP2023517242A (ja) 2020-03-12 2023-04-24 ビオンド バイオロジックス リミテッド 安定性が高められた脱落遮断剤
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4157460A1 (de) 2020-06-01 2023-04-05 HCW Biologics, Inc. Verfahren zur behandlung von altersbedingten erkrankungen
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4172323A1 (de) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Manipulierte viren zur förderung der a-otransmission und deren verwendung bei der behandlung von krebs
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
US20240182572A1 (en) 2021-04-09 2024-06-06 Ose Immunotherapeutics Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
CA3252619A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-CD28 and anti-PSMA antibodies
WO2023168363A1 (en) 2022-03-02 2023-09-07 HCW Biologics, Inc. Method of treating pancreatic cancer
CN119384289A (zh) 2022-04-13 2025-01-28 免疫生物公司 用于治疗神经炎症性障碍的多链嵌合多肽
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
US12600801B2 (en) 2022-07-11 2026-04-14 Fred Hutchinson Cancer Center Single-domain antibodies that bind ROR1
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
AU2023356326A1 (en) 2022-10-06 2025-03-27 Bicara Therapeutics Inc. Multispecific proteins and related methods
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2026043909A1 (en) 2024-08-19 2026-02-26 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
WO2026043906A1 (en) 2024-08-19 2026-02-26 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
ZA91463B (en) 1990-01-25 1992-09-30 Bristol Myers Squibb Co Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody
WO1994028912A1 (en) 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Cd28 pathway immunosuppression
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody

Also Published As

Publication number Publication date
JP4066166B2 (ja) 2008-03-26
ES2353273T3 (es) 2011-02-28
DE60142794D1 (de) 2010-09-23
EP1345969A2 (de) 2003-09-24
JP2004516034A (ja) 2004-06-03
US20080038273A1 (en) 2008-02-14
WO2002051871A2 (fr) 2002-07-04
WO2002051871A3 (fr) 2002-08-15
DK1345969T3 (da) 2010-11-29
EP1345969B1 (de) 2010-08-11
US7723482B2 (en) 2010-05-25
PT1345969E (pt) 2010-11-17

Similar Documents

Publication Publication Date Title
DE60142794D1 (de) Antikörper gegen cd28
ATE265532T1 (de) Monoklonaler antikörper br110 und dessen anwendung
SI2345671T1 (sl) Optimizirane Fc-variante in postopki za njihovo izdelavo
DK1047781T3 (da) IL-18-receptorer
NO20041325L (no) Substanser
WO1998054225A3 (de) Human-cd28 spezifische monoklonale antikörper zur antigenunspezifischen aktivierung von t-lymphozyten
MX9603080A (es) Anticuerpos monoclonales inmuno-estimulantes.
DE69737592D1 (de) Mittel gegen juckreiz
DK0973550T3 (da) Antagonistiske anti-AVB3-integrin-antistoffer
PL354976A1 (en) Factor ix/factor ixa antibodies and antibody derivatives
MXPA04003291A (es) Uso de anticuerpos biespecificos para ragular respuestas inmunes.
TW200510459A (en) RG1 antibodies and uses thereof
ATE346869T1 (de) Agonistische antikörper gegen tie2
GB2382705A (en) System and method for on-line service creation
ATE442860T1 (de) Mikropartikel mit cd28-spezifischen monoklonalen antikoerpern
DE60138605D1 (de) Phenyl-substituierte indole als h3 histaminrezeptorantagonisten
NO20011162D0 (no) FremgangsmÕter og preparater for modulering av interaksjonen mellom APJ-reseptoren og HIV-viruset
TR200001313T2 (tr) Protein etkileşimlerini ve fonksiyonel ilişkileri kaydeden tarama sistemleri
ES2193102T3 (es) Compuestos de imidocromo en sistemas catalizadores para la polimerizacion de olefinas.
BR0015872A (pt) Agentes antitrombóticos
DK0840620T3 (da) IL-8-antagonister til behandling af astma
TR199903187A3 (tr) Kadife kumaslarin yüz-yüze dokunmasi için yöntem.
DE69828414D1 (de) Mukosale zytotoxische t-lymphozytenantwort
NO20001051D0 (no) Monoklonale antistoffer som binder testosteron
NO20080409L (no) Fremgangsmater og preparater til malsoking av IFNAR2

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1345969

Country of ref document: EP